MELK Knockout HAP1 Cell Line

The choice depends on whether you are studying MELK (maternal embryonic leucine zipper kinase)'s role as an AMPK-related kinase in cell cycle and stem cell biology or contextualizing it as a historically prominent cancer drug target. The Knockout line is the standard tool for asking whether MELK is required for predicted cellular functions — MELK was initially characterized as a kinase upregulated in many cancers and required for cancer cell proliferation, leading to clinical development of OTSSP167 (a MELK inhibitor). Overexpression is useful for studying MELK gain-of-function effects. Important historical context: Lin et al. (2017) and Sheltzer et al. demonstrated that MELK CRISPR knockout cancer cells continued to proliferate normally despite MELK loss, contrasting with earlier RNAi-based studies that reported MELK essentiality. OTSSP167 was later shown to have off-target effects accounting for some of its anti-cancer activity. The EDITGENE MELK Knockout in HAP1 provides a genuine genetic null background for rigorous MELK functional studies that complement the older RNAi literature. Rescue with wild-type or kinase-dead MELK is the standard specificity control. The knockout is particularly valuable as a critical specificity control for OTSSP167 and other MELK inhibitors — distinguishing MELK-dependent from off-target effects of these compounds.

Primary applications: • OTSSP167 specificity validation: critical genetic control for OTSSP167 (OTS167) — the clinical MELK inhibitor's anti-cancer effects in MELK-null cells reveal off-target contributions distinct from on-target MELK inhibition. • MELK substrate phosphorylation: phospho-CDC25B and other reported MELK substrates Western blot analysis to characterize MELK kinase activity. • AMPK-family kinase studies: parallel analysis with AMPK and other AMPK-related kinases for functional specialization characterization. • Discovery phosphoproteomics: identification of bona fide MELK-dependent phosphorylation events in clean genetic background. EDITGENE recommends this model for researchers investigating MELK kinase biology and as a critical specificity control for OTSSP167 and emerging MELK inhibitor pharmacology research.

Yes. MELK rescue experiments are well-established for kinase research: • Construct design: use a codon-modified MELK sequence with a small C-terminal tag (FLAG, HA). MELK has N-terminal kinase domain, UBA (ubiquitin-associated) domain, central regulatory region, and C-terminal KA1 (kinase-associated 1) domain — preserve all elements. • Kinase-dead rescue: K40R or D150A mutations in the catalytic kinase domain abolish kinase activity and serve as the standard specificity control. • T-loop phospho-mimetic rescue: T167 (T-loop activation site) E mutation generates constitutively active MELK for gain-of-function studies. • OTSSP167-resistant rescue: gatekeeper residue mutations (e.g., G89 to large residue) can confer OTSSP167 resistance — useful for confirming on-target inhibitor effects. • Functional readout: rescue should restore MELK substrate phosphorylation patterns; expectation of restored proliferation depends on context given the CRISPR/RNAi differential dependence finding. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.